Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Poland signals halt to Ukraine weapons transfers amid trade dispute
    • Canadian Sikhs hail Justin Trudeau for ‘vocalising’ their cause against India
    • Federal Reserve signals fresh rate rise this year and fewer cuts in 2024
    • Russia puts squeeze on oil market with diesel export ban
    • Saudi Arabia says solving Palestinian issue crucial to deal with Israel
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Rupert Murdoch steps down as chair of Fox and News Corp
      • Europe’s largest cruise company pushes for change to emissions rules
      • Frasers tries to pull Morgan Stanley boss into margin call legal fight
      • Goldman Sachs raises $15bn to buy stakes in private equity funds
      • Chelsea FC raises $500mn from Ares
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Monzo clients rush to sign up for BlackRock offering
      • Live news: Shares of SoftBank-backed chip group Arm dip below IPO price
      • Hedge funds add fuel to oil price rally with bets on rise above $100
      • Russia puts squeeze on oil market with diesel export ban
      • Instacart and Arm shares lose steam after IPO pops
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • What the most ‘Chinese’ smartphone yet tells us about politics
      • How to save your state pension
      • Rishi Sunak’s unwise retreat on climate policies
      • Sunak’s Conservatives are betting against the future
      • Lachlan’s accession won’t put an end to Murdoch family strife
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • FT Business Book of the Year 2023 — the shortlist
      • ‘There is no work to balance’: how shrinking budgets, Covid and AI shook up life in consulting
      • American Express’s Steve Squeri: ‘If you’re not ready for the upswing, you’ve missed’
      • The plight of the hidden carers in your workforce
      • FT Business Books — what to read this month
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Who’d invite the boss to dinner?
      • Bosses won’t like it but WFH is a happier way to work
      • Should you buy the iPhone 15 Pro Max?
      • Russian rock star Boris Grebenshikov: ‘Millions are afraid to think, afraid to speak out’
      • ‘No effort’ dinner parties are a delusion
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Jim O'Neill

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 15 August, 2023
      Global Economy
      Brics creator slams ‘ridiculous’ idea for common currency

      Jim O'Neill questions emerging nations bloc’s achievements as it considers expansion

      Jim O’Neill, former chief economist of Goldman Sachs
    • Wednesday, 7 December, 2022
      UK economy
      Labour to unveil new plan for supporting UK small business

      Shadow chancellor will announce drive for investment in start-ups after Jim O’Neill-led review

      Shadow chancellor Rachel Reeves and Jim O’Neill on a visit to start-up VR training company Moonhub in east London
    • Sunday, 24 July, 2022
      UK economy
      The UK needs a coherent economic strategy

      Conservative members must choose a leader who can tackle productivity problems with more imagination

    • Monday, 7 February, 2022
      UK economy
      Ex-Treasury minister Jim O’Neill slams UK government’s economic policy

      O’Neill tells Commons Treasury committee level of interest rates is ‘ridiculous’ and calls for greater investment and ‘massive devolution’

      Lord Jim O’Neill before the Treasury select committee
    • Thursday, 20 January, 2022
      Special ReportFT Health: Future of Antibiotics
      Antibiotic resistance kills over 1mn people a year, says study

      Research underscores the dangers of bacteria developing the ability to resist drugs

    • Monday, 29 November, 2021
      Global Economy
      Twenty years on, the Brics have disappointed

      The challenge of how these countries achieve higher prosperity across society remains unsolved

      People shop at a mall in Seoul. South Korea continues to be the sole shining example for those nations which genuinely aspire to the goal of high income status
    • Tuesday, 18 May, 2021
      Property sector
      Jim O’Neill takes control at flexible office start-up Second Home

      Provider hopes for post pandemic boom after previously struggling to open new sites

    • Friday, 30 April, 2021
      Football
      The beautiful game of football is in sore need of a credible regulator

      Hare-brained scheme for a European Super League shows it is time for the UK government to act

      Emanuel Santos illustration of Jim O’Neill story ‘The beautiful game is in sore need of a credible regulator’
    • Friday, 25 September, 2020
      English devolution
      UK ‘levelling up’ agenda requires more devolution, ex-minister says

      Jim O’Neill believes Covid crisis has shattered belief that ‘Whitehall knows best’

    • Saturday, 11 May, 2019
      English devolution
      Stockport offers Britain’s towns a blueprint for revival

      The area is tackling the problems that beset declining places close to big cities

      EDD0EA Stockport town centre Mersey Way,
    • Wednesday, 27 March, 2019
      Drugs research
      Industry must turn words into action on superbugs, says Jim O’Neill

      Biotech companies need big pharma to bring innovative antibiotics to market

      Christian LaVallee prepares solutions for polymerase chain reaction (PCR) tests at the Health Protection Agency in north London March 9, 2011. For decades scientists have managed to develop new medicines to stay at least one step ahead of the ever-mutating enemy, bacteria. Now, though, we may be running out of road. Methicillin-resistant Staphylococcus aureus, commonly known as MRSA, alone is estimated to kill around 19,000 people every year in the United States -- far more than HIV and AIDS -- and a similar number in Europe, and other drug-resistant superbugs are spreading. Picture taken March 9, 2011. To match Special Report ANTIBIOTICS/ REUTERS/Suzanne Plunkett (BRITAIN - Tags: HEALTH SCI TECH) - GM1E73V1BEN01
    • Monday, 29 October, 2018
      UK Budget
      Resources for regions dismissed as lacking substance

      Chancellor says investment will ‘fire up’ projects in northern England and Midlands

      Embargoed to 0001 Thursday May 19 File photo dated 21/11/11 of Lord Jim O'Neill, who has said that tackling antimicrobial resistance (AMR) is "absolutely essential", as he published a global action plan to prevent drug-resistant infections and defeat the rising threat of so-called superbugs. PRESS ASSOCIATION Photo. Issue date: Thursday May 19, 2016. The growing resistance to drugs used to treat infections should be treated as an "economic and security threat", according to his review of antibiotic resistance. See PA story HEALTH Antibiotics. Photo credit should read: Dominic Lipinski/PA Wire
    • Friday, 21 September, 2018
      Brexit
      Jeremy Corbyn’s Labour looks poised to shake up the status quo

      The UK opposition steps into an economic void left by a government grappling with Brexit

      Artwork fro FTWeekend Comment - issue dated 22.09.18
    • Friday, 13 April, 2018
      Health
      FT Health: Why ‘sin taxes’ are good economics

      Tackling NCDs, Jim O’Neill, bad news for night owls

      A man smokes outside the Bank of England in the City of London, Britain, December 12, 2017. REUTERS/Clodagh Kilcoyne - RC15C518C7A0
    • Saturday, 1 July, 2017
      UK politics
      Northern Powerhouse regains post-election ‘momentum’

      Jim O’Neill optimistic over project’s future after PM’s previous indifference

      The FT Money round table with contributors; Merryn Somerset Webb (FT Money columnist) James Mackintosh (Short View columnist) Ewen Cameron Watt (chief investment strategist, BlackRock Investment Institute) Anne Richards (chief investment officer, Aberdeen Asset Management) Jim O'Neill (not sure how to describe him these days - I'll ask)
    • Friday, 23 September, 2016
      UK economy
      Jim O’Neill resigns as Treasury minister

      Former Goldman Sachs executive upset at grammar schools, Hinkley Point and Northern Powerhouse plans

      The FT Money round table with contributors; Merryn Somerset Webb (FT Money columnist) James Mackintosh (Short View columnist) Ewen Cameron Watt (chief investment strategist, BlackRock Investment Institute) Anne Richards (chief investment officer, Aberdeen Asset Management) Jim O'Neill (not sure how to describe him these days - I'll ask)
    • Sunday, 31 July, 2016
      US & Canadian companies
      Ex-Goldman star threatens to quit over UK’s China policy

      Treasury minister Jim O’Neill seeks clarity on role after Hinkley Point delay

      Jim O'Neill, commercial secretary to the U.K. treasury, gestures as he speaks at the Bank of England Open Forum at the Guildhall in London on Wednesday, Nov. 11, 2015. The Open Forum is a conference on the role of markets in society that's being attended by officials, academics, religious leaders and members of the public. Photographer: Simon Dawson/Bloomberg *** Local Caption *** Jim O'Neill
    • Monday, 4 July, 2016
      Brexit
      Northern powerhouse plans must continue, says Jim O’Neill

      Treasury official threatens to quit if project is downgraded

      Jim O'Neill, former chairman of Goldman Sachs Asset Management, pauses during the London Conference at Lancaster House in London, U.K., on Tuesday, June 3, 2014. Euro-area inflation slowed more than economists forecast in May, cranking up pressure on the European Central Bank to deploy measures as soon as this week to kindle prices and drive growth. Photographer: Simon Dawson/Bloomberg *** Local Caption *** Jim O'Neill
    • Thursday, 19 May, 2016
      The FT ViewUK economy
      Pull together to prevent a superbug apocalypse

      Drug companies need market incentives to generate new antibiotics

      The GlaxoSmithKline building is pictured in Hounslow, west London, Britain, June 18, 2013. REUTERS/Luke MacGregor/File Photo
    • Thursday, 19 May, 2016
      Pharmaceuticals sector
      Big pharma hits back at tax to tackle superbugs

      Drugmakers say levy to fund R&D on antimicrobial resistance wrong way to address lack of new antibiotics

      epa02285094 A researcher looking through a microscope, at the microbiology lab of the UZ Antwerpen, in Wilrijk, Antwerp, 13 August 2010. Belgian media reported 12 August that in June, a man from Pakistani origin died in Belgium, following an infection with a new super bacteria, NDM-1, that is resistent against almost every antibiotic. A British article claiming a drug-resistant superbug came from India was "biased" and could be aimed against the countryÔs booming medical tourism industry, Indian medical professionals and scientists said 13 August. The study in the British medical journal The Lancet Infectious Diseases said a new antibiotic-resistant enzyme had emerged in India, Pakistan and Britain. EPA/JORGE DIRKX BELGIUM OUT
    • Wednesday, 18 May, 2016
      Pharmaceuticals sector
      Multibillion-dollar pharma levy proposed in superbugs battle

      UK minister wants ‘play or pay’ scheme in search for effective new antibiotics

    • Monday, 18 April, 2016
      Brain drain
      Northern Powerhouse project threatened by ‘brain drain’

      Calls for regional tax incentives as young people move to London while few head the other way

      A9W5H0 view of stocksbridge sheffield uk
    • Thursday, 11 February, 2016
      UK companies
      O’Neill ‘superbug’ review promotes wider use of vaccines

      Smarter vaccination policy crucial to prevent ‘slow-motion car crash’ on antibiotics

      Lord Jim O'Neill, Commercial Secretary to the Treasury, is heading a review into the threat posed by drug-resistant superbugs. He said the lack of accurate diagnostic tests was leading doctors to prescribe antibiotics in many cases where they have no benefit for patients
    • Tuesday, 8 December, 2015
      Global Economy
      Superbug panel wants limit on antibiotics used in animals

      Livestock in China harbouring bacteria resistant to colistin

    • Thursday, 22 October, 2015
      Pharmaceuticals sector
      Lord O’Neill seeks investment to prevent misuse of antibiotics

      Funds needed to improve rapid diagnosis of bacterial infections

      Lord Jim O'Neill, Commercial Secretary to the Treasury, is heading a review into the threat posed by drug-resistant superbugs. He said the lack of accurate diagnostic tests was leading doctors to prescribe antibiotics in many cases where they have no benefit for patients
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

    Tools

    PortfolioToday’s Newspaper (FT Digital Edition)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Visual and data journalism
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today’s Newspaper (FT Digital Edition)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In